Previous studies indicated that the use of antibiotics, which affects the composition and diversity of gut microbiota, was associated with poor immunotherapy outcomes in patients with advanced EGFR- NSCLC, both in European and Asian populations [24–26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.